Sector News

Sobi appoints Norbert Oppitz SVP, speciality care

October 20, 2017
Life sciences

Rare diseases healthcare company Swedish Orphan Biovitrum (Sobi) has appointed Norbert Oppitz as its senior vice president for its newly established business area speciality care.

Oppitz has over 30 years’ pharmaceutical and healthcare experience and was most recently a member of the executive committee of BSN Medical in charge of its Latin America business.

In previous capacities, he has led organisations as head of Latin America at Takeda as well as in country management roles at Roche and Aventis Pharma.

He said: “I am excited to join Sobi and I look forward to contributing to the future growth of the company by realising a strategy to build and develop a strong and vital speciality care business unit.”

The new role will see Oppitz work with corporate development and the regional and country organisations.

Guido Oelkers, president and CEO of Sobi, said: “We are delighted that Norbert could join Sobi, he is a true entrepreneur and his experience will be instrumental in realising our ambitions to bring Sobi to the next level as we look for external growth opportunities for our speciality care business.”

Source: PMLive

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend